Stock Report: Ironwood Pharmaceuticals Inc. Cl A (IRWD) Report Updated: May 20, 2013 | Print This Page

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human medicines. Its lead product candidate, linaclotide, is a guanylate cyclase type-C agonist that completed Phase III clinical trials for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The company also has a pipeline focused on the research and development of early development candidates and discovery research in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, respiratory diseases, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to co-develop and co-market linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CC, and other lower gastrointestinal conditions; and Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.